Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Synergistic effects of eIF4A and MEK inhibitors on proliferation of NRAS-mutant melanoma cell lines.

Cell cycle (Georgetown, Tex.) - 16 Sept 2016

Malka-Mahieu Hélène, Girault Isabelle, Rubington Margot, Leriche Melissa, Welsch Caroline, Kamsu-Kom Nyam, Zhao Qian, Desaubry Laurent, Vagner Stéphan, Robert Caroline

Abstract excerpt

Activating mutations of the NRAS (neuroblastoma rat sarcoma viral oncogene) protein kinase, present in many cancers, induce a constitutive activation of both the RAS-RAF-MEK-ERK mitogen-activated protein kinase (MAPK) signal transduction pathway and the PI(3)K-AKT-mTOR, pathway. This in turn regulates the formation of the eIF4F eukaryotic translation initiation complex, comprising the eIF4E cap-binding protein,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Line, Tumor
Share to Cell Proliferation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Drug Synergism

Share to GTP Phosphohydrolases

Share to Melanoma

Share to Mitogen-Activated Protein Kinase Kinases

Share to Protein Kinase Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 27533468
DOI: 10.1080/15384101.2016.1208862
PMCID: PMC5026796

Genes

NRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Synergistic effects of eIF4A and MEK inhibitors on proliferation of NRAS-mutant melanoma cell lines.PMID 27533468Read ↗

Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo.Semantic proximity Read ↗

Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma.Semantic proximity Read ↗

BRAF and MEK inhibitor combinations induce potent molecular and immunological effects in NRAS-mutant melanoma cells: Insights into mode of action and resistance mechanisms.Semantic proximity Read ↗

Transcriptional Antagonism by CDK8 Inhibition Improves Therapeutic Efficacy of MEK Inhibitors.Semantic proximity Read ↗

A screen for combination therapies in <i>BRAF/NRAS</i> wild type melanoma identifies nilotinib plus MEK inhibitor as a synergistic combinationSemantic proximity Read ↗

Cotargeting MNK and MEK kinases induces the regression of NF1-mutant cancers.Semantic proximity Read ↗

Cooperative induction of apoptosis in NRAS mutant melanoma by inhibition of MEK and ROCK.Semantic proximity Read ↗

Preclinical Therapeutic Synergy of MEK1/2 and CDK4/6 Inhibition in NeuroblastomaSemantic proximity Read ↗

Combinational Inhibition of the eIF4F Complex, AKT1, and EZH2 Enhances Anticancer Effects in BRAFV600E Mutant A375 Melanoma Cells.Semantic proximity Read ↗

Combined targeting of BRAF and CRAF or BRAF and PI3K effector pathways is required for efficacy in NRAS mutant tumors.Semantic proximity Read ↗

Targeting Mnks for Cancer TherapySemantic proximity Read ↗

Mutant NRASQ61 shares signaling similarities across various cancer types--potential implications for future therapies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.